Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY] (ANP or Company) has today lodged a prospectus (Prospectus) with the Australian Securities and Investments Commission and with the Australian Securities Exchange in relation to a bonus offer of new options (New Options) in the Company. The prospectus follows this announcement. The Company intends to issue the New Options to eligible shareholders in Australia, New Zealand, Singapore and Hong Kong (Eligible Shareholders) on a pro rata basis for nil consideration to provide all supportive shareholders a benefit of greater exposure to the potential future success of the Company. The number of New Options to be issued under the Prospectus approximates the shortfall of the options that were not allocated under the Company's prospectus lodged with ASIC on 5 November 2021. If fully exercised, the New Options, combined with options issued in December 2021, will raise approximately $36 million to help fund the clinical program beyond the planned futility analysis. The New Options will rank equally in all respects with the options issued by the Company under the prospectus lodged with ASIC on 5 November 2021. The Offer will give all Eligible Shareholders an opportunity to receive one free unlisted option for every 20 Shares held at 7:00pm on the Record Date (as set out in the indicative timetable below) exercisable at $0.48 per option. The New Options will not be quoted on the ASX and will expire at 5.00pm (Melbourne time) on the earlier of:

(together, the Expiry Date). Funds received by the Company from the exercise of New Options, which are exercisable at any time prior to the Expiry Date, are to be primarily used to help fund the ATL1102 for DMD Phase IIb/III clinical trial in Europe and the follow on Open Label Extension Study. Key Dates

Event	Date* (Australian Eastern Standard Time)
Lodgement of this Prospectus	Tuesday 12 April 2022
Record Date for the Offer	7.00pm on Wednesday 20 April 2022
Offer opens	9.00am on Thursday 21 April 2022
Offer closes	5.00pm on Wednesday 27 April 2022
Allotment of New Options	Thursday 28 April 2022
Dispatch of holding statements	Friday 29 April 2022

*  The timetable is indicative only and subject to change.  The Company retains the discretion, subject to the ASX Listing Rules and the